Peptide deformylase inhibitors

1. A method of treating a bacterial infection by administering a compound according to formula (I):

wherein

X is C or O

n is 1 or 2, and

Ar is an aryl group selected from the group consisting of phenyl, azaindolyl, pyridyl, indolyl, quinolinyl, pyrazinyl, benzenethiophenyl, isoxazolyl, isoquinolinyl, napthyl, oxazolyl, isothiazolyl, benzothiaphenyl, furyl, pyridazinyl, thienyl, benzofuryl, imidazolyl, and thiazolyl, wherein Ar may be optionally substituted with one, two, or three substituents selected from the group consisting of optionally substituted alkyl or cycloalkyl of one to nine carbons, halo, alkoxy of one to nine carbons, hydroxy, amino, hydroxyalkyl of one to nine carbons, alkoxyalkyl, wherein the alkyl and alkylene groups are independently of one to nine carbons, optionally substituted aryl or optionally substituted heteroaryl, azaindolyl, carboxy, and alkoxycarbonyl or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 wherein the Ar group is selected from the group consisting of:

2-(3-Phenyl-5-Azaindole), 7-Quinoline, 5-Isoquinoline, Phenyl, 3-Methyl-2-pyridyl, 2-Trifluoromethylphenyl, 3-Bromophenyl, 2-Benzyloxyphenyl, 3-Chloro-4-fluorophenyl, 3,5-Dichlorophenyl, 2,3-Dichlorophenyl, 4-(3-Methyl propionate) phenyl, 4-Acetylphenyl, 4-Chloro- 3-methyiphenyl, 3-Chloro-4-methylphenyl, Naphthalene, 2,4,5-Trifluorophenyl, 2-Chiorophenyl, and 3-Hydroxyphenyl or a pharmaceutically acceptable salt thereof.

3. A method according to claim 2 wherein the compound is selected from the group consisting of:

N-Formyl-N-hydroxy-2-[3-(5-azaindole)phenoxy]ethylamine;

N-Formyl-N-hydroxy-2-(7-quinolinoxy)ethylamine;

N-Formyl-N-hydroxy-2-(5-isoquinolinoxy)ethylamine;

N-Formyl-N-hydroxy-3-phenylpropylamine;

N-Formyl-N-hydroxy-4-phenylbutylamine;

N-Formyl-N-hydroxy-3-(3-methyl-2-pyridyl)propylamine;

N-Hydroxy-(2-phenoxyethyl)formamide;

N-Formyl-N-hydroxy-2-(2 trifluoromethylphenoxy)ethylamine;

N-Formyl-N-hydroxy-2-(3-bromophenoxy)ethylamine;

N-Formyl-N-hydroxy-2-(2-benzyloxyphenoxy)ethylamine;

N-Formyl-N-hydroxy-2-(3-chloro-4-fluorophenoxy)ethylamine;

N-Formyl-N-hydroxy-2-(3,5-dichlorophenoxy)ethylamine;

N-Formyl-N-hydroxy-2-(2,3-dichlorophenoxy)ethylamine;

N-Formyl-N-hydroxy-2-[4-(3-methylpropionate)phenoxy]ethylamine;

N-Formyl-N-hydroxy-2-(4-acetylphenoxy)ethylamine;

N-Formyl-N-hydroxy-2-(4-chloro-3-methylphenoxy)ethylamine;

N-Formyl-N-hydroxy-2-(3-chloro-4-methylphenoxy)ethylamine;

N-Formyl-N-hydroxy-2-(naphthalen-1-yloxy)ethylamine;

N-Formyl-N-hydroxy-2-(naphthalen-2-yloxy)ethylamine;

N-Formyl-N-hydroxy-2-(2,4,5-trifluorophenoxy)ethylamine;

N-Formyl-N-hydroxy-2-(2-chlorophenoxy)ethylamine; and

N-Formyl-N-hydroxy-2-(3-hydroxyphenoxy)ethylamine; or a pharmaceutically acceptable salt thereof.

4. A method according to claim 1 of treating a bacterial infection wherein the bacterial infection is a respiratory tract infection.

5. A method according to claim 1 of treating a bacterial infection wherein the bacterial infection is Gram positive infection.

6. A method according to claim 1 of treating a bacterial infection wherein the bacterial infection is an infection with staphylococci, streptococci, or enterococci.

7. A method according to claim 2 of treating a bacterial infection wherein the bacterial infection is a respiratory tract infection.

8. A method according to claim 2 of treating a bacterial infection wherein the bacterial infection is Gram positive infection.

9. A method according to claim 2 of treating a bacterial infection wherein the bacterial infection is an infection with staphylococci, streptococci, or enterococci.

10. A method according to claim 3 of treating a bacterial infection wherein the bacterial infection is a respiratory tract infection.

11. A method according to claim 3 of treating a bacterial infection wherein the bacterial infection is Gram positive infection.

12. A method according to claim 3 of treating a bacterial infection wherein the bacterial infection is an infection with staphylococci, streptococci, or enterococci.

13. A method according to claim 1 wherein the pharmaceutically acceptable salt is a HCl, HBr, or trifluoroacetate salt.

14. A method according to claim 2 wherein the pharmaceutically acceptable salt is a HCl, HBr, or trifluoroacetate salt.

15. A method according to claim 3 wherein the pharmaceutically acceptable salt is a HCl, HBr, or trifluoroacetate salt.

16. A method according to claim 1 which comprises a daily dosage regimen for oral administration of about 0.01 mg/Kg to 40 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof.